Literature DB >> 31031166

Transient hepatic elastography has the best performance to evaluate liver fibrosis in non-alcoholic fatty liver disease (NAFLD).

Cristiane V Tovo1, Cristiane A Villela-Nogueira2, Nathalie C Leite2, Carine L Panke3, Gabriela Z Port3, Sabrina Fernandes3, Caroline Buss3, Gabriela P Coral3, Ana C Cardoso2, Claudia M Cravo2, Fernanda L Calçado2, Guilherme F M Rezende2, Frederico C Ferreira2, João M Araujo-Neto2, Renata de M Perez2, Henrique S Moraes-Coelho2, Angelo A de Mattos3.   

Abstract

INTRODUCTION AND AIM: The gold-standard for fibrosis diagnosis in non-alcoholic fatty liver disease (NAFLD) is liver biopsy, despite its invasive approach, sampling limitations and variability among observers. The objective was to validate the performance of non-invasive methods (Fibroscan™; APRI, FIB4 and NAFLD score) comparing with liver biopsy in the evaluation of liver fibrosis in patients with NAFLD.
MATERIAL AND METHODS: NAFLD patients ≥18 years of age who were submitted to liver biopsy were included and evaluated at two reference tertiary hospitals in Brazil with transient hepatic elastography (THE) assessment through Fibroscan™, APRI, FIB4 and NAFLD scores were determined. Sensitivity, specificity, positive (PPV) and negative (NPV) predictive values for the diagnosis of advanced fibrosis were calculated to evaluate the performance of these non-invasive methods in NAFLD patients, adopting liver biopsy as the gold standard.
RESULTS: A total of 104 patients were studied. At three different cutoff values (7.9, 8.7 and 9.6kPa) THE presented the highest sensitivity values (95%, 90% and 85% respectively), and the highest NPV (98%, 96.4% and 95.1% respectively) for the diagnosis of advanced fibrosis. It also presented the highest AUROC (0.87; CI 95% 0.78-0.97).
CONCLUSION: When compared to the gold standard, transient hepatic elastography presented the best performance for the diagnosis and exclusion of advanced fibrosis in patients with NAFLD, overcoming APRI, FIB4 and NAFLD score.
Copyright © 2019 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Non-invasive; Steatohepatitis; Steatosis

Year:  2019        PMID: 31031166     DOI: 10.1016/j.aohep.2018.09.003

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  8 in total

1.  Reduced and more appropriate referrals of patients with type 2 diabetes using liver stiffness measurement compared to FIB-4.

Authors:  William Shanahan; Isha Bagwe; Mary Jane Brassill; Paud O'Regan
Journal:  Ir J Med Sci       Date:  2022-04-29       Impact factor: 1.568

2.  Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis.

Authors:  Yu-Tian Cao; Liu-Lan Xiang; Fang Qi; Yu-Juan Zhang; Yi Chen; Xi-Qiao Zhou
Journal:  EClinicalMedicine       Date:  2022-07-10

Review 3.  Overview of the Pathogenesis, Genetic, and Non-Invasive Clinical, Biochemical, and Scoring Methods in the Assessment of NAFLD.

Authors:  Viera Kupčová; Michaela Fedelešová; Jozef Bulas; Petra Kozmonová; Ladislav Turecký
Journal:  Int J Environ Res Public Health       Date:  2019-09-24       Impact factor: 3.390

4.  Hyperuricemia Is Associated with Significant Liver Fibrosis in Subjects with Nonalcoholic Fatty Liver Disease, but Not in Subjects without It.

Authors:  Pei-Chia Yen; Yu-Tsung Chou; Chung-Hao Li; Zih-Jie Sun; Chih-Hsing Wu; Yin-Fan Chang; Feng-Hwa Lu; Yi-Ching Yang; Chih-Jen Chang; Jin-Shang Wu
Journal:  J Clin Med       Date:  2022-03-07       Impact factor: 4.241

5.  Pediatric percentiles for transient elastography measurements - effects of age, sex, weight status and pubertal stage.

Authors:  Lina Brunnert; Ika Damayanti Puasa; Antje Garten; Melanie Penke; Susanne Gaul; Nico Grafe; Thomas Karlas; Wieland Kiess; Gunter Flemming; Mandy Vogel
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-27       Impact factor: 6.055

6.  Screening of Family Members of Nonalcoholic Fatty Liver Disease Patients can Detect Undiagnosed Nonalcoholic Fatty Liver Disease Among Them: Is There a Genetic Link?

Authors:  Shubham Jain; Ravi Thanage; Falguni Panchal; Pravin M Rathi; Renuka Munshi; Suhas S Udgirkar; Qais Q Contractor; Sanjay J Chandnani; Nair P Sujit; Partha Debnath; Anupam Singh
Journal:  J Clin Exp Hepatol       Date:  2020-10-10

7.  Impact of Long-Term Supplementation with Fish Oil in Individuals with Non-Alcoholic Fatty Liver Disease: A Double Blind Randomized Placebo Controlled Clinical Trial.

Authors:  Kátia Cansanção; Marta Citelli; Nathalie Carvalho Leite; María-Carmen López de Las Hazas; Alberto Dávalos; Maria das Graças Tavares do Carmo; Wilza Arantes Ferreira Peres
Journal:  Nutrients       Date:  2020-11-02       Impact factor: 5.717

8.  Ability of a Combined FIB4/miRNA181a Score to Predict Significant Liver Fibrosis in NAFLD Patients.

Authors:  Rodrigo Vieira Costa Lima; José Tadeu Stefano; Fernanda de Mello Malta; João Renato Rebello Pinho; Flair José Carrilho; Marco Arrese; Claudia P Oliveira
Journal:  Biomedicines       Date:  2021-11-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.